GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (LTS:0QYQ) » Definitions » Cyclically Adjusted PB Ratio

Gilead Sciences (LTS:0QYQ) Cyclically Adjusted PB Ratio : 5.02 (As of Jan. 18, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Gilead Sciences Cyclically Adjusted PB Ratio?

As of today (2025-01-18), Gilead Sciences's current share price is $91.43. Gilead Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 was $18.20. Gilead Sciences's Cyclically Adjusted PB Ratio for today is 5.02.

The historical rank and industry rank for Gilead Sciences's Cyclically Adjusted PB Ratio or its related term are showing as below:

LTS:0QYQ' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 3.56   Med: 6.22   Max: 27.1
Current: 5.02

During the past years, Gilead Sciences's highest Cyclically Adjusted PB Ratio was 27.10. The lowest was 3.56. And the median was 6.22.

LTS:0QYQ's Cyclically Adjusted PB Ratio is ranked worse than
81.4% of 656 companies
in the Drug Manufacturers industry
Industry Median: 2.11 vs LTS:0QYQ: 5.02

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Gilead Sciences's adjusted book value per share data for the three months ended in Sep. 2024 was $14.827. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $18.20 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Gilead Sciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Gilead Sciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Cyclically Adjusted PB Ratio Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.83 4.71 5.04 5.27 4.59

Gilead Sciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.28 4.59 4.06 3.78 4.58

Competitive Comparison of Gilead Sciences's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, Gilead Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Cyclically Adjusted PB Ratio falls into.



Gilead Sciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Gilead Sciences's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=91.43/18.2
=5.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Gilead Sciences's adjusted Book Value per Share data for the three months ended in Sep. 2024 was:

Adj_Book=Book Value per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=14.827/133.0289*133.0289
=14.827

Current CPI (Sep. 2024) = 133.0289.

Gilead Sciences Quarterly Data

Book Value per Share CPI Adj_Book
201412 10.291 99.070 13.819
201503 11.632 99.621 15.533
201506 11.057 100.684 14.609
201509 12.018 100.392 15.925
201512 13.034 99.792 17.375
201603 9.939 100.470 13.160
201606 11.672 101.688 15.269
201609 12.759 101.861 16.663
201612 14.418 101.863 18.829
201703 15.640 102.862 20.227
201706 17.364 103.349 22.351
201709 19.009 104.136 24.283
201712 15.628 104.011 19.988
201803 15.839 105.290 20.012
201806 16.722 106.317 20.923
201809 17.667 106.507 22.066
201812 16.683 105.998 20.937
201903 17.230 107.251 21.371
201906 17.858 108.070 21.982
201909 16.275 108.329 19.986
201912 17.792 108.420 21.830
202003 17.597 108.902 21.496
202006 14.376 108.767 17.583
202009 13.923 109.815 16.866
202012 14.515 109.897 17.570
202103 15.113 111.754 17.990
202106 15.712 114.631 18.234
202109 17.108 115.734 19.665
202112 16.801 117.630 19.000
202203 15.878 121.301 17.413
202206 16.137 125.017 17.171
202209 16.811 125.227 17.858
202212 17.033 125.222 18.095
202303 16.825 127.348 17.576
202306 16.966 128.729 17.533
202309 17.893 129.860 18.330
202312 18.324 129.419 18.835
202403 14.065 131.776 14.199
202406 14.674 132.554 14.727
202409 14.827 133.029 14.827

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Gilead Sciences  (LTS:0QYQ) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Gilead Sciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Gilead Sciences Headlines

No Headlines